Jane Pritchett Henderson - 02 Jan 2026 Form 4 Insider Report for Apogee Therapeutics, Inc. (APGE)

Reporting relationship: Chief Financial Officer
Issuer ticker: APGE
Reported as of: 02 Jan 2026
Net transaction value: -$609,146
SEC form: 4
Accepted by SEC: 06 Jan 2026, 20:00:42 UTC
Prior SEC filing: 23 Dec 2025
Next SEC filing: 04 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Matthew Batters, as attorney-in-fact for Jane Pritchett Henderson

Key filing fact

Jane Pritchett Henderson filed Form 4 for Apogee Therapeutics, Inc. (APGE) on 06 Jan 2026.

Key facts

This page summarizes Jane Pritchett Henderson's Form 4 filing for Apogee Therapeutics, Inc. (APGE).
4 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 06 Jan 2026, 20:00.

Change

Previous filing in this sequence was filed on 23 Dec 2025.
Current net transaction value: -$609,146.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001422304 Primary reporting owner

Henderson Jane

Relationship: Chief Financial Officer
Address: C/O APOGEE THERAPEUTICS, INC., 221 CRESCENT ST., BLDG. 17, STE. 102B, WALTHAM
Signature: /s/ Matthew Batters, as attorney-in-fact for Jane Pritchett Henderson
Signature date: 06 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

APGE transaction

Common Stock

Sale

Transaction value: $142,330
Shares: -1,920
Change %: -0.99%
Price: $74.13
Shares after: 191,451
Date: 02 Jan 2026
Ownership: Direct
Footnotes: F1, F2

APGE transaction

Common Stock

Sale

Transaction value: $306,816
Shares: -4,080
Change %: -2.1%
Price: $75.20
Shares after: 187,371
Date: 02 Jan 2026
Ownership: Direct
Footnotes: F1, F3

APGE transaction

Common Stock

Sale

Transaction value: $160,000
Shares: -2,000
Change %: -1.1%
Price: $80.00
Shares after: 185,371
Date: 06 Jan 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

APGE transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +83,690
Change %
Price: $0.000000
Shares after: 83,690
Date: 02 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 83,690
Exercise price: $75.78
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 4 footnotes

Footnote F1

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 27, 2024.

Footnote F2

The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $73.67 to $74.65, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

Footnote F3

The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $74.73 to $75.67, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

Footnote F4

This option represents the right to purchase 83,690 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments over a four-year period from the date of grant, subject to the Reporting Person's continued service to the Issuer.